Kathleen Gallagher
Corporate Officer/Principal bij AVIDITY BIOSCIENCES, INC.
Actieve functies van Kathleen Gallagher
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AVIDITY BIOSCIENCES, INC. | Corporate Officer/Principal | - | - |
Investor Relations Contact | 01-04-2021 | - | |
Public Communications Contact | 01-04-2021 | - |
Loopbaan van Kathleen Gallagher
Eerdere bekende functies van Kathleen Gallagher
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Public Communications Contact | 01-01-2003 | 01-10-2016 |
AKCEA THERAPEUTICS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - |
Opleiding van Kathleen Gallagher
Boston University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
Public Communications Contact | 3 |
Investor Relations Contact | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AVIDITY BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Kathleen Gallagher
- Ervaring